{"schema_version":"secwatch.filing_event.v1","accession":"0001759425-25-000053","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.355072+00:00","generated_at":"2026-05-17T00:40:01.405187+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Mirum Q3 revenue $133M, up 47% YoY; lifts FY guidance to $500-510M","bullets":["Q3 2025 total revenue $133.0M vs $90.4M in Q3 2024; LIVMARLI sales $92.2M (+56% YoY).","Bile Acid Medicines net sales $40.8M, up 31% YoY; cash and investments $378M.","Volixibat VISTAS (PSC) enrollment complete; topline data expected Q2 2026.","Volixibat VANTAGE (PBC) and LIVMARLI EXPAND enrollment expected 2026; topline H1 2027.","Phase 2 study of MRM-3379 for Fragile X Syndrome initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001759425-25-000053","json":"https://secwatch.observer/filing/0001759425-25-000053.json","markdown":"https://secwatch.observer/filing/0001759425-25-000053.md","text":"https://secwatch.observer/filing/0001759425-25-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/0001759425-25-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000175942525000053/mirm-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:40:01.405187+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}